TSLP
Assets acting on this target.
- Class
- Anti-TSLP monoclonal antibody
Thymic stromal lymphopoietin (TSLP) is a cytokine released by epithelial cells lining the airways, skin, and gut in response to irritants, allergens, viruses, and other environmental triggers. It acts as an early alarm signal, activating dendritic cells, mast cells, and lymphoid cells that in turn drive downstream type 2 immune responses, including production of interleukin-4, interleukin-5, and interleukin-13. Because TSLP sits near the top of this inflammatory cascade, blocking it can dampen multiple downstream effector pathways at once rather than neutralizing a single one, which distinguishes this approach from therapies aimed at individual interleukins. Anti-TSLP monoclonal antibodies bind circulating TSLP and prevent it from engaging its receptor complex on target cells, reducing initiation of the allergic and eosinophilic inflammatory cascade. This mechanism is of broad interest in diseases where epithelial barrier disruption and chronic type 2 inflammation contribute to pathology, most notably asthma, but also atopic dermatitis, chronic rhinosinusitis, and other allergic or eosinophilic conditions. Because TSLP acts upstream of both classical allergic (type 2 high) and less classical inflammatory phenotypes, TSLP-targeted therapy has been of interest for patient populations that do not respond well to therapies aimed narrowly at eosinophilic pathways.
Related mechanisms
TSLP drugs compared
9 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| tezepelumabTezspire | Amgen, AstraZeneca | monoclonal antibody | Approved | Approved in Asthma; Phase 3 in Chronic Obstructive Pulmonary Disease; Phase 3 in Eosinophilic Esophagitis |
| Felcorekibart | GlaxoSmithKline, Jiangsu Hengrui Pharmaceuticals | monoclonal antibody | Phase 3 | Phase 3 in Asthma; Phase 3 in Chronic Obstructive Pulmonary Disease; Phase 2 in Atopic Dermatitis |
| Ocankitug | Keymed Biosciences, Shanghai JMT-Bio | monoclonal antibody | Phase 3 | Phase 3 in Asthma; Phase 2 in Chronic Obstructive Pulmonary Disease |
| WIN378 | Harbour BioMed, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Windward Bio | monoclonal antibody | Phase 2/3 | Phase 2/3 in Asthma; Phase 2 in Chronic Obstructive Pulmonary Disease |
| Bosakitug | Aclaris Therapeutics, Biosion, Chia Tai Tianqing Pharmaceutical Group | monoclonal antibody | Phase 2 | Phase 2 in Atopic Dermatitis |
| Sunakiment | Amgen, AstraZeneca | antibody fragment | Phase 2 | Phase 2 in Asthma |
| GR2002 | Genrix Bio | bispecific antibody | Phase 1 | Phase 1 in Atopic Dermatitis |
| SKB575 | Harbour BioMed, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | bispecific antibody | Phase 1 | Phase 1 in Asthma; Phase 1 in Atopic Dermatitis |
| ABBV-333 | AbbVie | undisclosed | Stage not recorded | Not recorded |